Lactobacillus reuteri DSM 17938 and Reduced Antibiotic-Associated Diarrhea

• Effect of Limosilactobacillus reuteri DSM17938 to prevent antibiotic-associated diarrhea in children: prospective, multi-center, randomized, placebo-controlled clinical trial (PEARL Study).

  • 2025-06-09
  • RCT · n = 330
  • European journal of pediatrics 184(7)
  • • Ener Cagri Dinleyici
    • Metehan Ozen
    • Sirin Guven
    • Nazan Dalgic
    • Adem Karbuz
    • Murat Sutcu
    • Ozden Turel
    • Fatma Nur Oz
    • Ulviye Kirli
    • Sevgi Yasar Durmus
    • Ahmet Sami Yazar
    • Zeynep Ebru Cakin
    • Yvan Vandenplas
    • Ates Kara

  • PubMed: 40488914
  • DOI: 10.1007/s00431-025-06249-8

  2 Insights on

  • Reduced Antibiotic-Associated Diarrhea

  • High evidence
  • Large Human Trial
  • Clinical

  The percentage of children with AAD was significantly lower in the L. reuteri group compared to the placebo group at 14 days (7.9% vs. 16.7%; RR: 0.47, 95%CI 0.30-0.7; p < 0.001); at 21 days (8.8% vs. 17.9%; RR: 0.49, 95%CI 0.32-0.74;p < 0.001); and at 56 days (9.1% vs. 19.6%; RR: 0.46, 95%CI 0.30-0.69;p < 0.001).

  Effect

  Beneficial

  Effect size

  Large

  Significant

  Yes

  Dose

  2 × 10^8 CFU

• Systematic review: Limosilactobacillus reuteri DSM 17938 for preventing antibiotic-associated diarrhoea in children.

  • 2026-01-04
  • Systematic Review · n = 998
  • Journal of pediatric gastroenterology and nutrition 82(3)
  • • Hania Szajewska
    • Maciej Kołodziej
    • Bartłomiej M Zalewski
    • Ener Cagri Dinleyici
    • Jan Łukasik

  • PubMed: 41486369
  • DOI: 10.1002/jpn3.70320

  1 Insight on

  • Reduced Antibiotic-Associated Diarrhea

  • High evidence
  • Children

  A subgroup analysis limited to children receiving amoxicillin-clavulanate showed benefit (two RCTs, n = 690; RR: 0.49, 95% CI: 0.32-0.76; I² = 0%).

  Effect

  Beneficial

  Effect size

  Large

  Significant

  Yes